Addex Therapeutics (ADXN) Stock Price, News & Analysis

Company Overview

Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.

The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease. Additional programs include ADX71149, an mGlu2 positive allosteric modulator being investigated for mood and anxiety disorders, and early-stage GABAB receptor modulators. Addex employs proprietary drug discovery platforms to optimize targeting, selectivity and pharmacokinetic profiles, advancing multiple candidates through preclinical and clinical stages.

Addex Therapeutics serves global markets through strategic collaborations with pharmaceutical partners to co-develop and potentially commercialize its pipeline. The company’s integrated R&D operations in Europe and North America support translational research and clinical studies. Led by a management team with deep experience in neuroscience drug development, Addex seeks to bring innovative allosteric therapies to patients with debilitating neurological and psychiatric conditions.

Key Stats

• Today's Range: $3.10 to $3.42
• 50-Day Range: $3.26 to $6.35
• 52-Week Range: $3.10 to $11.97
• Volume: 24,182 shs
• Average Volume: 424,940 shs
• Market Capitalization: $4.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Addex Therapeutics Stock Analysis - MarketRank™

Addex Therapeutics scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Addex Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Addex Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Addex Therapeutics is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Addex Therapeutics is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Addex Therapeutics has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.39% of the float of Addex Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Addex Therapeutics has a short interest ratio ("days to cover") of 0.01, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Addex Therapeutics has recently decreased by 41.65%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Addex Therapeutics does not currently pay a dividend.

Dividend Growth

Addex Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.43

News Sentiment

Addex Therapeutics has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Addex Therapeutics this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Addex Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.00% of the stock of Addex Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

16.14% of the stock of Addex Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 11/22/2024
• Today: 9/15/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ADXN
• CIK: 1574232
• Web: www.addextherapeutics.com
• Phone: 011-41-22-884-1555
• Fax: 41-22-884-1556
• Employees: 30
• Year Founded: 2002

Profitability

• EPS (Trailing Twelve Months): ($5.94)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.12 million
• Net Margins: N/A
• Pretax Margin: -19,126.31%
• Return on Equity: -134.76%
• Return on Assets: -106.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.97
• Quick Ratio: 0.97

Sales & Book Value

• Annual Sales: $210 thousand
• Price / Sales: 19.09
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.67 per share
• Price / Book: 0.70

Miscellaneous

• Outstanding Shares: 1,230,000
• Free Float: 1,047,000
• Market Cap: $4.01 million
• Optionable: Not Optionable
• Beta: 1.47